Skip to main
GH
GH logo

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health has demonstrated a robust revenue trajectory, with a two-year revenue CAGR projected to increase by 28% from 2023 to 2025, supported by the anticipated growth in colorectal cancer (CRC) diagnostics, breast cancer indications, and new monitoring applications. The company's recent launch of Shield, which exceeded revenue expectations, and the anticipated continued strong performance of Reveal, its fastest-growing test, are key contributors to an optimistic revenue outlook, with 2025 revenue guidance reflecting a 31% year-over-year growth. Additionally, Guardant Health’s market capitalization is poised to surpass $10 billion, driven by significant share price appreciation and increasing investor interest in its innovative product portfolio and expansion efforts.

Bears say

Guardant Health's medium-term revenue guidance for its Shield product has been perceived as underwhelming, contributing to concerns over the company's growth potential. The company reported an adjusted EBITDA loss of $45.5 million in Q3 2025, reflecting financial challenges that could exacerbate stock volatility in the face of any negative news regarding regulatory issues, reimbursement, or product launch timelines. Additionally, the firm's executive commentary indicates that reliance on ongoing research and development funding, coupled with potentially delayed international expansion due to regulatory obstacles, could continue to hinder financial performance.

GH has been analyzed by 21 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 21 analysts, GH has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.